Rethinking Prevention of HIV Type 1 Infection
- 15 September 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 51 (6) , 725-731
- https://doi.org/10.1086/655889
Abstract
Research on the prevention of human immunodeficiency virus (HIV)-1 infection is at a critical juncture. Major methodological challenges to performing prevention trials have emerged, and one after another promising biomedical interventions have failed to reduce the incidence of HIV-1 infection. Nevertheless, there is growing optimism that progress can be achieved in the near term. Mathematical modeling indicates that 2 new strategies, "test and treat" and preexposure prophylaxis, could have a major impact on the incidence of HIV-1 infection. Will our hopes be justified? We review the potential strengths and limitations of these antiretroviral "treatment as prevention" strategies and outline other new options for reducing the incidence of HIV-1 infection in the near term. By maximizing the potential of existing interventions, developing other effective strategies, and combining them in an optimal manner, we have the opportunity to bring the HIV-1 epidemic under control.Keywords
This publication has 53 references indexed in Scilit:
- Addressing Research Priorities for Prevention of HIV Infection in the United StatesClinical Infectious Diseases, 2010
- Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settingsAIDS, 2010
- Knowledge of HIV status, sexual risk behaviors and contraceptive need among people living with HIV in Kenya and MalawiAIDS, 2009
- HIV-prevention science at a crossroads: advances in reducing sexual riskCurrent Opinion in HIV and AIDS, 2009
- HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost‐EffectivenessClinical Infectious Diseases, 2009
- Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical modelThe Lancet, 2009
- Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapyAIDS, 2008
- The Effect of Viral Suppression on Cross-Sectional Incidence Testing in the Johns Hopkins Hospital Emergency DepartmentJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital TractJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Adherence to MedicationNew England Journal of Medicine, 2005